Abstract
When Butler and Chen first produced digoxin antibodies in 19671 it was hoped that the availability of a radioimmunoassay of serum levels of digoxin would lead to safer and more effective use of digitalis glycosides. Most physicians would agree that this hope has been realized. Digitalis intoxication is occurring less often,2 and as special problems with the drug in specific disease states have been noted, management has improved.3 In addition, interactions of digitalis with other drugs have been recognized, and methods have evolved for dealing with them.4 5 6 The term "antibody," of course, suggested a potential for treatment of digitalis toxicity . . .

This publication has 7 references indexed in Scilit: